- Report
- February 2025
- 200 Pages
Global
From €4008EUR$4,490USD£3,485GBP
- Report
- January 2025
- 175 Pages
Global
From €4008EUR$4,490USD£3,485GBP
- Report
- August 2025
- 194 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP
- Report
- August 2025
- 197 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP
- Report
- August 2025
- 189 Pages
Global
From €3165EUR$3,545USD£2,752GBP
€3516EUR$3,939USD£3,057GBP
- Report
- October 2025
- 193 Pages
Global
From €5222EUR$5,850USD£4,541GBP
- Report
- December 2024
- 200 Pages
Global
From €3348EUR$3,750USD£2,911GBP
- Report
- April 2025
- 200 Pages
Global
From €5678EUR$6,360USD£4,937GBP
€7097EUR$7,950USD£6,171GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2142EUR$2,400USD£1,863GBP
€2678EUR$3,000USD£2,329GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1071EUR$1,200USD£931GBP
€1339EUR$1,500USD£1,164GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1428EUR$1,600USD£1,242GBP
€1785EUR$2,000USD£1,552GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €1785EUR$2,000USD£1,552GBP
€2232EUR$2,500USD£1,940GBP
- Report
- April 2025
- 200 Pages
Global
From €5678EUR$6,360USD£4,937GBP
€7097EUR$7,950USD£6,171GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1428EUR$1,600USD£1,242GBP
€1785EUR$2,000USD£1,552GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1071EUR$1,200USD£931GBP
€1339EUR$1,500USD£1,164GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1071EUR$1,200USD£931GBP
€1339EUR$1,500USD£1,164GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1071EUR$1,200USD£931GBP
€1339EUR$1,500USD£1,164GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1071EUR$1,200USD£931GBP
€1339EUR$1,500USD£1,164GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €893EUR$1,000USD£776GBP
€1116EUR$1,250USD£970GBP
- Report
- October 2025
Global
From €4374EUR$4,900USD£3,803GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more